Gastrointestinal Medical Oncology Clinic

Comparison of Whole Body DWI to FDG PET

The overall proportion of lesions that will be characterized as positive on whole body (WB) diffusion weight imaging (DWI) and FDG PET.

Recruiting

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

The proportion of patients who achieve a greater than 50% decline from baseline prostate specific antigen (PSA) (PSA50) drawn prior to C1D1, at any point in the treatment course, will be descriptively reported along with 95% binom...

Recruiting

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastat...

PSA progression is defined as a rise in PSA at > 12 weeks by more than 25% and more than 2ng/mL above the nadir (lowest PSA point).

Recruiting

18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas

Sensitivity of 18F-fluorocholine PET for the detection of abnormal parathyroid adenomas confirmed by pathology as compared to sestamibi imaging. Location of parathyroid adenoma at imaging as read by three blinded readers, will be ...

Recruiting

TheraSphere With Durvalumab and Tremelimumab for HCC

Complete response and partial response evaluated by mRECIST.

Recruiting

Addressing the Nutritional Needs of Cancer Survivors With Nutrition Insecurity

The FIM is a four-item measure of implementation that assesses participants perceived appropriateness of the intervention. Each item response falls on a scale of 1 (Completely disagree) to 5 (Completely agree). A scaled score is c...

Recruiting

Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable H...

Tumor-infiltrating immune cells (TIICs) will be analyzed by immunohistochemistry (IHC) in pre- and post-pembrolizumab treatment tumor specimens. The proportion of patients with a >= 2-fold increase (from pre- to post-treatment) in...

Recruiting

Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer

To determine the recommended phase II dose (RP2D) hydroxychloroquine in combination with trametinib.

Recruiting

Imaging of Solid Tumors Using FAP-2286

The frequency and severity of treatment emergent adverse events following FAP-2286 injection will be descriptively reported as classified and graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI ...

Recruiting

Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286

Proportion of participants with Adverse Events, as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 will be reported.

Recruiting